Key Takeaways
- Gilead Sciences finalized its $7.8 billion purchase of Arcellx on April 28, 2026, securing complete ownership of anito-cel, a CAR T-cell treatment designed for multiple myeloma patients.
- The stock is revisiting an 11-year cup base breakout zone at the $123.47 pivot point, with one market watcher projecting a year-end price of $173 — representing potential upside of 35%.
- Shares have fallen 8% during April while climbing 22% over the trailing twelve months; current trading occurs around the $128 mark.
- Technical indicators show GILD’s RSI reaching 27, marking the most oversold reading observed in at least twelve months, with the 200-day SMA providing support in close proximity.
- The acquisition will impact GAAP and non-GAAP 2026 diluted EPS negatively by $5.57–$5.67, though analysts anticipate positive contributions starting in 2028, subject to regulatory clearance.
Gilead Sciences wrapped up its acquisition of Arcellx on April 28, delivering $115 per share in cash alongside a contingent value right worth $5 per share. The combined implied equity value reached approximately $7.8 billion at closing.
This transaction provides Gilead with complete ownership of anitocabtagene autoleucel, commonly known as anito-cel, an investigational BCMA-directed CAR T-cell therapy focused on treating multiple myeloma. Before this acquisition, Gilead and Arcellx maintained a collaborative partnership through Kite, Gilead’s specialized cell therapy division.
Acquiring Arcellx entirely allows Gilead to avoid ongoing profit-sharing arrangements, milestone payments, and royalty commitments. This strategic move enables the pharmaceutical giant to accelerate development timelines and make commercialization choices more efficiently.
The additional $5 CVR per share triggers only when cumulative worldwide net sales of anito-cel reach a minimum of $6 billion between product launch and the conclusion of 2029. While this represents a substantial threshold, it demonstrates strong expectations regarding the therapy’s market opportunity.
Cindy Perettie, Gilead’s leader of Kite operations, stated the priority now centers on “executing with speed and discipline” while the organization prepares to deliver anito-cel to patients. The Arcellx team along with its D-Domain BCMA binder platform will merge into Kite’s existing manufacturing capabilities and regulatory framework.
Regarding financial implications, this transaction will decrease Gilead’s GAAP and non-GAAP 2026 diluted EPS by $5.57 to $5.67. Setting aside acquired in-process R&D costs, the merger is forecast to create modest dilution during 2026 and 2027, transitioning to accretive contributions beginning in 2028 — contingent upon FDA authorization of anito-cel.
Arcellx shares will be removed from the Nasdaq Global Select Market after the merger reaches completion.
Chart Analysis
From a technical perspective, GILD occupies a noteworthy position. The shares are revisiting an 11-year cup base breakout occurring at the $123.47 pivot level — a formation tracing back to bearish candlestick formations observed during June and July 2015.
Extended timeframe breakouts historically demonstrate elevated success probabilities, making this retest particularly relevant for traders. The RSI metric has descended to 27, a depth unseen for at least twelve months, indicating significantly oversold territory. The 200-day simple moving average sits close by and previously provided support during May and October of the previous year.
GILD has experienced losses in eight out of the previous 10 weeks, with April alone accounting for an 8% decline. Both March and April’s downward movements occurred alongside lighter volume readings, which certain chart analysts interpret as a potentially favorable development.
Biotech Sector Dynamics
The SPDR S&P Biotech ETF has advanced 9% during 2026, contrasting with struggles in the wider healthcare sector, which has dropped 7% and ranks as the poorest performer among the 11 primary S&P sectors. The iShares Biotechnology ETF, listing Gilead as its top holding at nearly 8% of total assets, has generated returns below 1% year to date.
GILD shows a 4% year-to-date gain and 22% appreciation across the past 12 months despite recent weakness. One chart specialist has established a $173 price objective for year end, suggesting 35% potential appreciation from present levels near $128. The optimistic scenario remains viable provided shares maintain positions above $118.
Gilead concluded its tender offer for Arcellx on April 28, with submitted shares accounting for roughly 77.2% of Arcellx’s total outstanding stock.
